Abstract: The process described herein discloses purification process of a secondary metabolite produced by fermentation route. The process involves selective removal of impurities at various stages of washings, charcoalization followed by crystallization. The product is closely related to class of echinocandins and is found to be potent antifungal compound & a key ingredient in the synthesis of antifungal drugs.

Abstract: The process described herein discloses purification process of a secondary metabolite produced by fermentation route. The process involves selective removal of impurities at various stages of washings, charcoalization followed by crystallization. The product is closely related to class of echinocandins and is found to be potent antifungal compound & a key ingredient in the synthesis of antifungal drugs.

Abstract: The present disclosure provides solution to the problems involved in determining the crystallinity of sirolimus. More particularly, the instant disclosure is successful in providing a method to determine crystallinity of sirolimus or its analogues using Near-Infrared [NIR] spectroscopy. Also, the instant disclosure provides a method for crystallization of sirolimus or its analogues.

Abstract: The present invention is successful in providing a suitable process for the isolation and purification of geldanamycin. The process provided in the instant invention is easy to scale-up, industrially safe and will give high yield and productivity.

Abstract: The present invention relates to a pure form of rapamycin with a total impurity content less than 1.2%; a process for recovery and purification of rapamycin comprising steps of (a) treating the fermentation broth, extracts or solutions containing rapamycin with water immiscible solvent and concentration; (b) addition of a water miscible solvent to effect separation of impurities present; (c) optionally, binding of the solvent containing the product from step (b) to an inert solid, washing the solid with a base and acid, followed by elution; (d) subjecting the elute from step (c) or the solvent containing the product from step (b) to silica gel chromatography; (e) crystallization of the product obtained from step (d); (f) subjecting a solution of the product from step (e) to hydrophobic interaction or reversed phase chromatography; and (g) re-crystallization to afford rapamycin in substantially pure form.